EMEA-001943-PIP01-16-M07 - paediatric investigation plan
ravulizumab
PIPHuman
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com
Tel: +33 147100615
P/0188/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-001943-PIP01-16-M07)